Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.8552W HIGH $3.82
Volume
1.22 M
Value Traded
1.13 M
Short % Float
16.35%
-3.57%Week
-50.54%1 Month
-64.48%3 Month
-66.02%6 Month
-85.15%5 Year
-87.98%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
59.49 M
EPS (TTM)
-1.10
P/E Ratio
-
Ent. Value
28.01 M
Total Shares
62.97 M
Float Shares
16.97 M
Insiders
73.05%
Institutions
22.10%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
CNTB Catalyst Timeline
Dated clinical, regulatory and corporate events for Connect Biopharma Holdings Limited
Catalyst Timeline
Dated clinical, regulatory & corporate events for Connect Biopharma Holdings Limited
243Total events
6Upcoming
72Tier-1 (high impact)
2021 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Secondary Endpoint DataRademikibartFiledClinical Data
Rademikibart reduced new moderate to severe COPD exacerbations by 85% through Week 4
acute exacerbations in adults with COPD and type 2 inflammationsource ↗
▲Topline ReadoutRademikibartFiledClinical Data
Positive preliminary topline data from global Phase 2 Seabreeze STAT COPD study of rademikibart
acute exacerbations in adults with COPD and type 2 inflammationsource ↗
▲Safety Data UpdateRademikibartFiledClinical Data
Rademikibart well tolerated with lower incidence of adverse events than placebo
acute exacerbations in adults with COPD and type 2 inflammationsource ↗
▲Primary Endpoint MetRademikibartFiledClinical Data
Rademikibart met primary endpoint, reducing treatment failure rate by 81% vs placebo through Week 4
acute exacerbations in adults with COPD and type 2 inflammationsource ↗
●R&D DayPresentation
Connect Biopharma to host conference call and webcast to discuss topline data
▲Topline ReadoutRademikibartFiledClinical Data
Positive preliminary topline data from global Phase 2 Seabreeze STAT Asthma study of rademikibart
acute exacerbations in adult and adolescent participants with asthma and type 2 inflammationsource ↗
▼Primary Endpoint MissedRademikibartFiledClinical Data
Primary endpoint of treatment failure at 28 days missed statistical significance (66% reduction; p=0.153)
acute exacerbations in adult and adolescent participants with asthma and type 2 inflammationsource ↗
▲Secondary Endpoint DataRademikibartFiledClinical Data
Statistically significant improvement in post-bronchodilator FEV1 at Day 7 (250 mL vs 120 mL placebo; p=0.023)
acute exacerbations in adult and adolescent participants with asthma and type 2 inflammationsource ↗
▲Safety Data UpdateRademikibartFiledClinical Data
Rademikibart well tolerated with no new safety signals; one SAE vs 3 SAEs in placebo arm
acute exacerbations in adult and adolescent participants with asthma and type 2 inflammationsource ↗
●Quarterly UpdateCorporate
Company-hosted conference call and webcast to discuss topline data
▲Primary Endpoint MetRademikibartFiledClinical Data
Statistically significant improvement in post-bronchodilator FEV1 at Day 7 (250 mL vs 120 mL placebo; p=0.023)
acute exacerbations in adult and adolescent participants with asthma and type 2 inflammationsource ↗
◆Topline ReadoutRademikibartFiledClinical Data
Topline data from Phase 2 Seabreeze STAT COPD study of rademikibart expected later this month
acute exacerbations in COPD patients with type 2 inflammationsource ↗
◆Timing GuidanceRademikibartFiledPresentation
Plans to engage with FDA to gain alignment on a Phase 3 registrational development program for rademikibart
acute exacerbations of asthma and COPDsource ↗
▲Trial InitiationRademikibartFiledTrial
Initiated Phase 2 Seabreeze STAT IV study
acute exacerbations in asthma or COPD with type 2 inflammationsource ↗
▲Enrollment CompleteRademikibartFiledTrial
Completed enrollment in Phase 2 Seabreeze STAT asthma and COPD studies
acute exacerbations in asthma and COPDsource ↗
▲Milestone PaymentRademikibartFiledCorporate
Achieved regulatory-based milestone under Simcere license agreement
▲Enrollment CompleteRademikibartFiledTrial
Completed enrollment in Phase 2 Seabreeze STAT Asthma study
acute exacerbations in asthma with type 2 inflammationsource ↗
▲Enrollment CompleteRademikibartFiledTrial
Expected completion of enrollment in Phase 2 Seabreeze STAT COPD study this month
acute exacerbations in COPD with type 2 inflammationsource ↗
◆Oral PresentationPresentation
Fireside chat at H.C. Wainwright 4th Annual BioConnect Investor Conference
▲Interim AnalysisRademikibartFiledTrial
DMC completed pre-specified interim analysis of efficacy with no recommendation for change in sample size
acute exacerbations of asthmasource ↗
◆Topline ReadoutRademikibartFiledClinical Data
Topline data expected from Phase 2 Seabreeze STAT studies
acute exacerbations in asthma and COPDsource ↗
▲Interim AnalysisRademikibartFiledTrial
Independent DMC review of pre-specified interim analysis with no recommendation for change in sample size and no safety concerns
acute exacerbations of asthma and COPDsource ↗
▲Topline ReadoutRademikibartFiledClinical Data
Positive topline data from Phase 1 IV study of rademikibart in asthma or COPD
asthma or COPDsource ↗
◆Oral PresentationRademikibartFiledPresentation
Phase 3 rademikibart AD results presented in late-breaking session at AAD
moderate-to-severe atopic dermatitissource ↗
▲Full ResultsRademikibartFiledClinical Data
Phase 3 RADIANT-AD 52-week results announced
moderate-to-severe atopic dermatitissource ↗
▲Topline ReadoutRademikibartFiledClinical Data
Positive topline data from Phase 1 IV study of rademikibart in asthma and COPD patients
asthma or COPDsource ↗
◆Enrollment UpdateRademikibartFiledTrial
Recruitment ongoing for Phase 2 Seabreeze STAT studies
acute exacerbations in asthma and COPDsource ↗
▲Late-BreakerRademikibartFiledPresentation
Late-breaking oral presentation of Phase 3 RADIANT-AD 52-week results at AAD 2026
moderate-to-severe atopic dermatitissource ↗
▲Oral PresentationRademikibartFiledPresentation
Late-breaking oral presentation at AAD 2026
moderate-to-severe atopic dermatitissource ↗
◆Oral PresentationPresentation
Fireside chat at Leerink Partners Global Healthcare Conference
▲Topline ReadoutRademikibartFiledClinical Data
Positive topline data from Phase 1 IV clinical pharmacology study
stable asthma or COPDsource ↗
▲Oral PresentationRademikibartFiledPresentation
Phase 3 AD results presented at 2026 American Academy of Dermatology Annual Meeting
moderate-to-severe atopic dermatitissource ↗
◆Oral PresentationPresentation
Oppenheimer 36th Annual Healthcare Life Sciences Conference presentation
◆Topline ReadoutRademikibartFiledClinical Data
Anticipated topline data read-out from Phase 2 Seabreeze STAT studies
acute asthma exacerbationssource ↗
◆FDA ApprovalCBP-201FDA Decision
Potential NDA approval in China targeted for 2025
moderate-to-severe atopic dermatitissource ↗
◆Enrollment UpdateRademikibartFiledTrial
Recruitment ongoing for Phase 2 Seabreeze STAT studies
acute exacerbations in asthma and COPDsource ↗
▲FDA Filing AcceptedRademikibartFiledRegulatory Filing
NDA for rademikibart accepted by China's NMPA
atopic dermatitissource ↗
◆Poster PresentationRademikibartFiledPresentation
Poster presentation: Rademikibart in Moderate-to-Severe Asthma: Impact of Eosinophils and Regional Differences on Response
Moderate-to-Severe Asthmasource ↗
◆Oral PresentationRademikibartFiledPresentation
Data presented at ERS Congress 2025 supporting rademikibart in type 2 asthma
asthmasource ↗
◆Oral PresentationPresentation
H.C. Wainwright 27th Annual Global Investment Conference Fireside Chat
Past FDA Catalysts and PDUFA Decisions
How CNTB actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-09-30 | rademikibart | Phase 2 topline data readout | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D32 / 100
Pipeline Score
$23M
Pipeline Value
Overvalued
Valuation Signal
5
Drugs Scored
0.4x
rNPV / MCap
Top 62%
Micro Cap(rank 408 of 658)
Percentile Rank
Connect Biopharma Holdings Limited faces pipeline headwinds (32/100), with $1.1B risk-adjusted pipeline value, led by Rademikibart in Asthma Acute (Phase 2), across $81B in total addressable markets, but cash runway is a concern.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Rademikibart Small moleculeNCT06940141 | Asthma Acute | Phase 2 | COMPLETED | 200 | Aug 10, 2026 |
Clinical Trial Results
Readouts, endpoints and source filings for every CNTB program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| rademikibart | COPD and type 2 inflammation | Phase 2 | 2026-09-30 | 81% reduction in treatment failure (p=0.0122); 85% reduction in new moderate to severe COPD exacerbations (p=0.030); 100% reduction in hospitalizations or emergency department visits for new acute COPD exacerbations (p=0.0137)Read More | Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adults with COPD and Type 2 InflammationRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Xanthopoulos Kleanthis GabrielDirector | Grant/Award | 3,738 86,554 held | $0.00 | 06/30/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in CNTB
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | 0 % | 1.89 M | 792.70 K |
CNTB Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-03-19 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How CNTB ranks across every disease it competes in
Competitive Position is a premium feature
See how CNTB ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialCNTB News
CNTB▲ +10.9%on this news
Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adults with COPD and Type 2 Inflammation
Connect Biopharma announced positive topline results from its Phase 2 study of rademikibart, showing significant reductions in treatment failure and COPD exacerbations. The drug demonstrated a 100% reduction in hospital visits for acute exacerbations and was well tolerated. The company plans to engage with the FDA for a Phase 3 program.
Read more →CNTB▼ -32.2%on this news
Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adult and Adolescent Participants with Asthma and Type 2 Inflammation
Connect Biopharma announced positive topline results from its Phase 2 study of rademikibart, showing a 66% reduction in treatment failure for asthma exacerbations. The study demonstrated significant improvements in lung function within a week. The company plans to engage with the FDA for a Phase 3 program following additional data from a COPD study.
Read more →CNTBConnect Biopharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Connect Biopharma Holdings Limited will participate in the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026. The company focuses on treatments for inflammatory diseases, particularly asthma and COPD, and is advancing its candidate rademikibart. An exclusive licensing agreement with Simcere Pharmaceutical for Greater China could yield substantial milestone payments.
Read more →CNTB▲ +9%on this news
Connect Biopharma Reports Second Quarter 2026 Financial Results and Provides Business Update
Connect Biopharma has completed enrollment in its Phase 2 Seabreeze STAT studies for asthma and COPD, with topline results anticipated in September 2026. The company reported a net loss of $17.3 million for the second quarter of 2026, while its cash runway is expected to last at least one year. Following the results, Connect plans to engage with the FDA regarding a potential Phase 3 program for rademikibart.
Read more →CNTBConnect Biopharma Announces Completion of Enrollment of Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma
Connect Biopharma has completed enrollment in its Phase 2 Seabreeze STAT Asthma study, which evaluates rademikibart for treating acute asthma exacerbations. The company expects to report topline data in early September 2026 and aims to finalize enrollment in the Seabreeze STAT COPD study soon. With a solid financial foundation, Connect is preparing to engage with the FDA regarding a Phase 3 program.
Read more →CNTB▼ -8.6%on this news
Connect Biopharma to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference
Connect Biopharma Holdings Limited will participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 2026. The company is focused on developing rademikibart, a next-generation antibody for treating asthma and COPD. An archived replay of the presentation will be available for 90 days post-conference.
Read more →CNTB▲ +14.5%on this newsshared move
Connect Biopharma Reports First Quarter 2026 Financial Results and Provides Business Update
Connect Biopharma has reported its first-quarter financial results for 2026, indicating a net loss of $19.4 million. The company is progressing in its Phase 2 Seabreeze STAT studies for asthma and COPD, expecting topline data by mid-2026. A recent $20.2 million financing bolsters its operations, allowing for ongoing development of rademikibart, which has shown promising preliminary results. Despite financial challenges, management remains optimistic about the product's potential in the market.
Read more →CNTBConnect Biopharma Announces Enrollment in Phase 2 Seabreeze STAT Studies Will Continue as Planned Following Pre-Specified Interim Analysis - Expect to report topline data from both studies mid-2026
Connect Biopharma announced that enrollment in its ongoing Phase 2 Seabreeze STAT studies for rademikibart will proceed as planned. The independent Data Monitoring Committee confirmed the efficacy analysis without recommending any changes to sample size. Rademikibart continues to show positive tolerability among patients, and topline results are expected to be reported by mid-2026. The company is also aligning with the FDA for future Phase 3 program development.
Read more →CNTBConnect Biopharma Reports 2025 Full-Year Financial Results and Provides Business Update
Connect Biopharma reported its 2025 financial results, highlighting significant progress in its lead drug candidate, rademikibart. The company released positive data from a Phase 1 study and is currently recruiting for Phase 2 studies aimed at asthma and COPD. Additionally, a $20.2 million equity financing was secured to support ongoing operations.
Read more →CNTB▼ -15.9%on this newsshared move
Connect Biopharma Announces $20.2 Million Private Placement Financing
Connect Biopharma has announced a private placement financing of $20.2 million, which will extend its cash runway into the second half of 2027. The financing involves the sale of 6,130,000 shares at $3.25 each, led by its largest investor, Panacea Venture. The funds will support research and development of clinical-stage products and general corporate purposes.
Read more →CNTB▼ -15.9%on this newsshared move
Rademikibart Demonstrates Best-in-Class Potential in Phase 3 Atopic Dermatitis Study
Connect Biopharma announced positive results from a Phase 3 study of rademikibart for moderate-to-severe atopic dermatitis. The study demonstrated significant efficacy with ~90% of patients achieving near-maximal responses. Safety was comparable to placebo, with low rates of conjunctivitis. The findings were presented at the 2026 American Academy of Dermatology Annual Meeting.
Read more →CNTB▼ -15.9%on this newsshared move
Connect Biopharma Announces Positive Topline Data from its Phase 1 Study of Intravenous (IV) Rademikibart in Patients with Asthma or COPD
Connect Biopharma announced positive topline results from its Phase 1 study of intravenous rademikibart, showing rapid and sustained improvements in lung function for asthma and COPD patients. The study demonstrated significant FEV1 improvements as early as 15 minutes post-dosing, with effects maintained through Day 29. The company plans to advance to Phase 2 studies and engage with the FDA for a Phase 3 program.
Read more →CNTB▲ +5.3%on this news
Results from Phase 3 Study of Rademikibart in Moderate-to-Severe Atopic Dermatitis to be Presented in the Late-Breaking Research Session at the 2026 American Academy of Dermatology (AAD) Annual Meeting
Connect Biopharma announced that results from a Phase 3 study of rademikibart for moderate-to-severe atopic dermatitis will be presented at the 2026 AAD Annual Meeting. The study, conducted by Simcere Pharmaceutical, has shown promising results which may support the approval of Simcere's NDA in China. Connect Biopharma sees potential for rademikibart in treating atopic dermatitis beyond China.
Read more →CNTBConnect Biopharma to Present at the Leerink Partners Global Healthcare Conference
Connect Biopharma Holdings Limited will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on March 10, 2026. The event will be accessible via a live webcast, with an archived replay available for 90 days. The company is focused on developing rademikibart, a treatment for asthma and COPD, and has a licensing agreement with Simcere Pharmaceutical for the drug in Greater China.
Read more →CNTBConnect Biopharma to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Connect Biopharma Holdings Limited will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026. The company focuses on innovative treatments for inflammatory diseases, particularly asthma and COPD. They are advancing their therapy, rademikibart, which targets IL-4Rα and is currently undergoing global clinical trials. Connect has also established a collaboration with Simcere Pharmaceutical for the commercialization of rademikibart in Greater China.
Read more →CNTBConnect Biopharma Highlights New Mechanism of Action Data for Rademikibart and Outlines Priorities for 2026
Connect Biopharma has revealed new data supporting the unique mechanism of action for its drug rademikibart, highlighting its potential for rapid airway improvement. The company is currently recruiting patients for both Phase 1b and Phase 2 clinical studies targeting asthma and COPD, with topline results expected through mid-2026. Financially, Connect Biopharma has a solid cash position, likely sustaining operations through key clinical developments into 2027. Additional studies provide evidence of improved efficacy compared to existing treatments, suggesting rademikibart may effectively address significant unmet medical needs.
Read more →CNTBConnect Biopharma to Present at the 8th Annual Evercore Healthcare Conference
Connect Biopharma Holdings Limited has announced its participation in the 8th Annual Evercore Healthcare Conference, scheduled for December 2nd, 2025. The company will engage in a fireside chat about its clinical-stage products, including rademikibart, designed to treat asthma and COPD. Connect is currently conducting global clinical studies and has licensed its product for distribution in Greater China. This involvement highlights the company's commitment to advancing treatment options in inflammatory diseases.
Read more →CNTB▲ +5.9%on this news· ran to +64% by day 3
Connect Biopharma Reports Third Quarter 2025 Financial Results and Provides Business Update
Connect Biopharma reported its third quarter 2025 financial results, highlighting ongoing recruitment for Phase 2 Seabreeze STAT studies targeting acute exacerbations in asthma and COPD. The company announced that the New Drug Application for rademikibart, aimed at treating atopic dermatitis, was accepted by China's NMPA. Additionally, positive data was presented at ERS 2025 regarding rademikibart's efficacy.
Read more →CNTB▼ -16.6%on this news
Connect Biopharma Presents Data Supporting Rademikibart at the European Respiratory Society Congress 2025
Connect Biopharma presented promising data for rademikibart at the ERS Congress 2025, highlighting its efficacy in improving lung function and asthma control, particularly in patients with elevated inflammatory markers. The findings support ongoing Phase 2 studies for asthma and COPD, with topline data anticipated in early 2026. The company aims to establish rademikibart as a leading treatment option in these areas.
Read more →CNTB▼ -10.6%on this news
Connect Biopharma Announces Two Presentations at the European Respiratory Society (ERS) Congress 2025
Connect Biopharma announced two poster presentations at the European Respiratory Society Congress 2025, focusing on their product rademikibart for asthma treatment. The presentations will take place on September 29, 2025, and will cover the impact of eosinophils on treatment response. Rademikibart targets interleukin-4 receptor alpha, aiming to block inflammatory pathways associated with asthma.
Read more →About Connect Biopharma Holdings Limited
Headquarters3580 CARMEL MOUNTAIN ROAD, SUITE 200, SAN DIEGO, CA, 92130
BIOPHARMAWATCH ELITE PLUS
Trade the next CNTB catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime